The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: A European expert recommendation

Schnell O., Alawi H., Battelino T., Ceriello A., Diem P., Felton A., ...More

Journal of Diabetes Science and Technology, vol.6, no.3, pp.665-673, 2012 (Scopus) identifier identifier

  • Publication Type: Article / Review
  • Volume: 6 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.1177/193229681200600323
  • Journal Name: Journal of Diabetes Science and Technology
  • Journal Indexes: Scopus
  • Page Numbers: pp.665-673
  • Keywords: Diabetes, Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 analogs, Hypoglycemia, Self-monitoring, Treatment
  • Istanbul University Affiliated: Yes


The role of glucagon-like peptide (GLP)-1-based treatment approaches for type 2 diabetes mellitus (T2DM) is increasing. Although self-monitoring of blood glucose (SMBG) has been performed in numerous studies on GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, the potential role of SMBG in GLP-1-based treatment strategies has not been elaborated. The expert recommendation suggests individualized SMBG strategies in GLP-1-based treatment approaches and suggests simple and clinically applicable SMBG schemes. Potential benefits of SMBG in GLP-1-based treatment approaches are early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education. Its length and frequency should depend on the clinical setting and the quality of metabolic control. It is considered to play an important role for the optimization of diabetes management in T2DM patients treated with GLP-1-based approaches. © Diabetes Technology Society.